JPRN-jRCT2080223072未知2 期
A phase 2, randomized, placebo-controlled, double-blind, crossover study of DS-8500a to evaluate the effects on pancreatic beta cell function in Japanese patients with type 2 diabetes mellitus
适应症
试验速览
- 阶段
- 2 期
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Main Inclusion Criteria;
- •1)Patients aged >= 20 years
- •2)Japanese patients with type 2 diabetes mellitus
- •3)Patients who have >= 7.0% and < 9.0% HbA1c
排除标准
- •Main Exclusion Criteria;
- •-Patients with type 1 diabetes mellitus or with a history of diabetic coma, precoma, or ketoacidosis
- •-Patients receiving or requiring treatment with insulin
- •-Patients with a body mass index (BMI) of < 18.5 kg/m2 or >= 35.0 kg/m2
- •-Patients with clinically evident renal impairment (estimated glomerular filtration rate [eGFR] of < 45 mL/min per 1.73 m2) or clinically significant renal disease
- •-Patients with fasting plasma glucose >= 240 mg/d
研究者
相似试验
进行中（未招募）
2 期
A phase 2, randomized, placebo-controlled, double-blind, dose-finding study of TS-172 in hyperphosphatemia patients on hemodialysisHyperphosphatemiaJPRN-jRCT2031220587Mita Seiji150
已完成
2 期
A phase 2 study of TAS-303 in female patients with stress urinary incontinenceStress urinary incontinenceJPRN-jRCT2080225307Taiho Pharmaceutical Co., Ltd.186
进行中（未招募）
1 期
A phase II randomized, placebo-controlled, double-blind, dose-escalation study to evaluate safety, pharmacokinetics and pharmacodynamic dose response relationship of IFX-1 in patients undergoing complex cardiac surgery (CARDIAC)Prevention of organ dysfunction induced by inflammatory response after complex cardiac surgeryMedDRA version: 20.0Level: PTClassification code 10063101Term: Post procedural inflammationSystem Organ Class: 10022117 - Injury, poisoning and procedural complicationsMedDRA version: 20.0Level: LLTClassification code 10062357Term: SIRSSystem Organ Class: 100000004867EUCTR2015-003036-12-DEInflaRx GmbH
进行中（未招募）
1 期
A Clinical Study to evaluate Ladarixin as an additional therapy to improve glycemic control in overweight insulin resistance patients with type 1 diabetes.EUCTR2022-000743-68-ITDOMPé FARMACEUTICI S.P.A.86
进行中（未招募）
1 期
A phase II randomized, placebo-controlled, double-blind, dose controlled trial in patients suffering from early, newly developing abdominal or pulmonary derived septic organ dysfunction to evaluate safety, pharmacokinetics, pharmacodynamics and to estimate efficacy of the new humanized monoclonal i.v. administered antibody CaCP29EUCTR2013-001037-40-DEInflaRx GmbH72